Clearside Biomedical Inc (CLSD) - Total Assets
Based on the latest financial reports, Clearside Biomedical Inc (CLSD) holds total assets worth $11.64 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Clearside Biomedical Inc - Total Assets Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's total assets have evolved over time, based on quarterly financial data. Also see CLSD market cap overview for the company's overall valuation and market capitalisation.
Clearside Biomedical Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Clearside Biomedical Inc's total assets of $11.64 Million consist of 84.7% current assets and 15.3% non-current assets. Review CLSD total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.7% |
| Accounts Receivable | $507.00K | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Clearside Biomedical Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Clearside Biomedical Inc's current assets represent 84.7% of total assets in 2024, a decrease from 93.1% in 2012.
- Cash Position: Cash and equivalents constituted 79.7% of total assets in 2024, down from 90.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 2.0% of total assets.
Clearside Biomedical Inc Competitors by Total Assets
Key competitors of Clearside Biomedical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Clearside Biomedical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.98 | 4.49 | 1.82 |
| Quick Ratio | 2.98 | 4.49 | 1.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.48 Million | $19.52 Million | $8.18 Million |
Clearside Biomedical Inc - Advanced Valuation Insights
This section examines the relationship between Clearside Biomedical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.93 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -26.1% |
| Total Assets | $25.13 Million |
| Market Capitalization | $2.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Clearside Biomedical Inc's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Clearside Biomedical Inc's assets decreased by 26.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Clearside Biomedical Inc (2012–2024)
The table below shows the annual total assets of Clearside Biomedical Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $25.13 Million | -26.14% |
| 2023-12-31 | $34.02 Million | -33.69% |
| 2022-12-31 | $51.30 Million | +19.58% |
| 2021-12-31 | $42.90 Million | +122.04% |
| 2020-12-31 | $19.32 Million | -27.84% |
| 2019-12-31 | $26.78 Million | -39.31% |
| 2018-12-31 | $44.12 Million | +8.96% |
| 2017-12-31 | $40.49 Million | -52.26% |
| 2016-12-31 | $84.81 Million | +302.82% |
| 2015-12-31 | $21.05 Million | +104.44% |
| 2014-12-31 | $10.30 Million | +381.94% |
| 2013-12-31 | $2.14 Million | +125.42% |
| 2012-12-31 | $948.00K | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more